http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Pyridoxine Refractory Sideroblastic Anemia: Diagnosis and Misdiagnosis
Muhammad Matloob Alam,Abdulrhman Alathaibi,Ruwayd Adel Attar,Muhammad Kashif,Hamdan Saeed Al-Ghamdi,Sultan Abdulaziz Alharthi,Abdulmohsen Bokhary,Muteb Althomali 대한소아혈액종양학회 2022 Clinical Pediatric Hematology-Oncology Vol.29 No.2
We report the case of a 7-year-old girl who was originally diagnosed at the age of 6 months with transfusion-dependent red cell aplasia based on a combination of se-vere anemia, reticulocytopenia and bone marrow findings. Since early infancy due to severe microcytic/hypochromic anemia she received multiple packed RBCs transfusions. She subsequently developed hepatomegaly, hypothyroidism, diabetes, liver cirrhosis and latterly, a severe cardiomyopathy due to significant iron overload refractory to regular chelating agents. Genetic study was offered, confirmed the pres-ence of SLC25A38 gene mutation and her diagnosis was revised to pyridoxine re-fractory sideroblastic anemia (PRSA). It is a non-syndromic, autosomal recessive dis-order, characterized by severe microcytic anemia since infancy and increased serum ferritin, which is not responsive to pyridoxine. Since the clinical course of this dis-order is very similar to that of thalassemia major and other red cell aplasia. Prompt recognition and initiation of appropriate treatment are important to reduce the de-velopment of secondary disease complications due to iron overload. Given the poten-tial for misdiagnosis and delay in the recognition of sideroblastic anemia, a careful bone marrow examination and genetic study should be included while investigating children with unexplained anemia.